title: HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
abstract: Immune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles in HIV-1 negative ethnic Thai recipients of an HIV-1 prime boost vaccine regimen, designed to induce neutralizing antibody (NAb) responses to HIV-1 CRF01_AE. Non-response to vaccine associated with DRB1*11 (3/32 responders vs. 7/13 non-responders, p(c)=0.027) and DRB1*16:02 (0/32 responders vs. 4/13 non-responders, p(c)=0.078) alleles. Furthermore, vaccine recipients with HLA-DQ heterodimers encoded by DQA1*05:01 and DQB1*03:01 alleles, were much less likely to produce NAb (p=0.009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians.
authors.affiliation: Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. robert.paris@us.army.mil
authors.forename: Robert
authors.initials: R
authors.lastname: Paris
authors.forename: Sasitorn
authors.initials: S
authors.lastname: Bejrachandra
authors.forename: Prasert
authors.initials: P
authors.lastname: Thongcharoen
authors.forename: Sorachai
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: Punnee
authors.initials: P
authors.lastname: Pitisuttithum
authors.forename: Anna
authors.initials: A
authors.lastname: Sambor
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gurunathan
authors.forename: Donald
authors.initials: D
authors.lastname: Francis
authors.forename: Silvia
authors.initials: S
authors.lastname: Ratto-Kim
authors.forename: Chitraporn
authors.initials: C
authors.lastname: Karnasuta
authors.forename: Mark S
authors.initials: MS
authors.lastname: de Souza
authors.forename: Victoria R
authors.initials: VR
authors.lastname: Polonis
authors.forename: Arthur E
authors.initials: AE
authors.lastname: Brown
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
authors.forename: Henry A
authors.initials: HA
authors.lastname: Stephens
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000483:Alleles; D057134:Antibodies, Neutralizing / Q000097:blood*; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood*; D000949:Histocompatibility Antigens Class II / Q000235:genetics* / Q000276:immunology*; D006805:Human Experimentation; D006801:Humans; D013785:Thailand
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D000949:Histocompatibility Antigens Class II